GENE ONLINE|News &
Opinion
Blog

WuXi Biologics Acquires Bayer’s Drug Manufacturing Facility in Wuppertal

by Tyler Chen
Share To

Following the Bayer manufacturing plant buyout in Leverkusen, Germany in January, Shanghai-based WuXi Biologics is now going to end the year with another plant acquisition from Bayer.

 

$ 183 Million Buyout

On December 21, WuXi Biologics entered into an agreement with Bayer for obtaining the Drug Substance manufacturing site at Wuppertal with a deal close to $183.3 million (€150 million). Both parties are planning on initiating a long-term sublease agreement and transition service contract.

It is the second time in 2020, WuXi Biologics gains a pharmaceutical factory in Germany.

 

The Role of Manufacturing Site in Wuppertal

MFG19 located in Wuppertal, Germany is around 30,000 square meters and equipped with 3x1000L perfusion and 6x2000L fed-batch capacity with independent downstream suites.

Purchase of MFG19 will complement the Leverkusen plant (DP7) to strengthen its supply chain to deliver more COVID-19 vaccines and other biologics. Also, MFG19 will be used for commercial manufacturing to meet the increasing demand globally.

Both procured sites are estimated to get into motion by 2021, and the transaction is expected to close in the first half of 2021.

 

About WuXi

WuXi Biologics provides a proprietary one-stop open-access biologics technology platform. It’s used to discover, develop, and manufacture biologics from concept to manufacturing.

WuXi Biologics has around 286 integrated projects by June 30. 141 projects are in the pre-clinical development stage, 125 in early-phase clinical trials, 19 projects in Phase 3 trials, and one is currently in the manufacturing stage.

By Tyler Chen

Related Article: Is Bayer’s Entry to the Gene Therapy Market Worth its Investment?

References
  1. https://www.wuxibiologics.com/News_Media-Press_Release-2020-12_21_WuXi_Biologics_to_Acquire_Drug_Substance_Facility_in_Wuppertal_Germany_from_Bayer.html
  2. https://media.bayer.com/baynews/baynews.nsf/id/Bayer-and-WuXi-Biologics-enter-into-an-agreement-on-a-Leverkusen-drug-product-plant

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
New Trends of Hospital Pharmacy Expenditure: Specialty and Neurology Medications are Escalating
2023-08-09
Bayer Signs Up To Google Cloud To Boost Drug Discovery
2023-01-13
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top